Key Performance
More- Earnings Score: N/A
- Momentum Score: 33
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
Procept BioRobotics CEO Larry Wood purchased 23,900 shares (~$498,000) through a trust on August 7, 2026, expanding his beneficial stake to 338,103 shares. The purchase occurred as the stock declined 48% over the past year, but comes after the company reported 19% Q2 sales growth and Wood's reorganization efforts. Insider purchases are typically viewed as bullish signals, suggesting management confidence in the company's turnaround prospects despite ongoing net losses of $109.8 million on $337.3 million in trailing revenue.
08/18/2026, 6:11 PM • The Motley Fool
A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about product demand. The company allegedly used undisclosed discount programs to inflate handpiece unit sales, resulting in overstocking. PROCEPT's stock fell over 18% on February 25, 2026, when the company revealed that handpiece sales had consistently exceeded procedures. Investors have until September 22, 2026, to seek lead plaintiff status.
08/09/2026, 10:55 AM • GlobeNewswire
Rosen Law Firm is encouraging investors who purchased securities of Microvast Holdings (MVST) between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion. The lead plaintiff deadline is September 21, 2026. Similar class action notices are being issued for PROCEPT BioRobotics and TransMedics Group.
08/09/2026, 10:00 AM • GlobeNewswire
Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures. The company allegedly accumulated over 10,000 excess units in field inventory and was unable to achieve its 2025 guidance. The lead plaintiff deadline is September 22, 2026.
08/09/2026, 9:17 AM • GlobeNewswire
PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). The company is accused of misleading investors about U.S. handpiece sales that exceeded procedures, resulting in over 10,000 units of excess inventory that would cause significant revenue declines. Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.
08/07/2026, 10:51 AM • GlobeNewswire
Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 - February 25, 2026). The firm is also pursuing cases against Hub Group, Inc. and investigating potential securities violations at Alignment Healthcare, Inc. Investors with losses are encouraged to contact the firm before respective deadlines.
08/07/2026, 10:45 AM • GlobeNewswire
Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.
08/07/2026, 9:32 AM • GlobeNewswire
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging securities fraud. The company allegedly failed to disclose an extensive discount program that artificially inflated handpiece sales and revenues between February 2024 and February 2026. The undisclosed practices led to excess field inventory exceeding 10,000 units and significant stock price declines following quarterly earnings announcements. Shareholders who purchased PROCEPT securities during the class period have until September 22, 2026 to file a lead plaintiff motion.
08/05/2026, 3:55 PM • GlobeNewswire
Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.
08/04/2026, 11:49 AM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding sales practices. The lawsuit claims PROCEPT used undisclosed discount programs to artificially inflate handpiece unit sales and revenues, created excess inventory of over 10,000 units, and provided unrealistic 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is September 22, 2026.
08/03/2026, 11:24 PM • GlobeNewswire
Robbins Geller has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging that the company and its executives made materially false and misleading statements regarding undisclosed discount programs that artificially inflated sales figures and created excess field inventory. The lawsuit covers investors who purchased PRCT stock between February 28, 2024 and February 25, 2026. Multiple stock price declines followed earnings announcements revealing lower-than-expected handpiece sales and inventory management issues.
08/03/2026, 7:50 AM • GlobeNewswire
Rosen Law Firm has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The firm claims the company's 2025 guidance lacked a reasonable factual basis. Investors must move the court by September 22, 2026 to serve as lead plaintiff.
07/31/2026, 9:27 PM • GlobeNewswire
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging the company issued materially false statements regarding its handpiece unit sales and revenues. The complaint claims PROCEPT used an undisclosed discount program to artificially inflate sales figures, created excess field inventory of over 10,000 units, and failed to disclose material risks. The lead plaintiff deadline is September 22, 2026.
07/31/2026, 10:27 AM • GlobeNewswire
The Gross Law Firm has announced securities class action lawsuits against Helen of Troy Limited (HELE) and other companies for allegedly making false and misleading statements. HELE is accused of misrepresenting the expected savings and effectiveness of Project Pegasus. The deadline for shareholders to register as potential lead plaintiffs is August 3, 2026.
07/31/2026, 10:27 AM • GlobeNewswire
The Gross Law Firm has issued notices regarding multiple securities class action lawsuits. Insulet Corporation faces allegations of defective manufacturing controls and misleading statements regarding product safety, with a lead plaintiff deadline of August 31, 2026. Similar class action notices were issued for PROCEPT BioRobotics Corporation and Helen of Troy Limited, with deadlines in September 2026.
07/31/2026, 10:23 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 08/21/2026
Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.